Abstract: The present invention relates to a novel compound as an mTOR inhibitor and a use thereof and, more specifically, to a novel compound represented by formula 1 that exhibits mTOR inhibitory activity and a pharmaceutical composition comprising same as an active ingredient for preventing or treating brain diseases associated with an mTOR pathway.

Abstract: The present invention relates to a method for screening an anticancer agent which inhibits the binding of AIMP2-DX2 and HSP70. In addition, the pharmaceutical composition for preventing or treating cancer comprising, as an active ingredient, an anticancer agent screened according to the method of the present invention inhibits the expression of HSP70 or inhibits the binding of HSP70 and AIMP2-DX2, thereby lowering the level of AIMP2-DX2 protein, and can effectively prevent the progression of cancer. As such, the pharmaceutical composition can be useful for developing a cancer treating agent.

Abstract: The present invention relates to a colorectal cancer diagnostic composition and method for detecting a diagnostic marker, more specifically to a colorectal cancer diagnostic composition comprising one or more mRNAs selected from the group consisting of lysyl-tRNA synthetase (KRS) and aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1) of a preparation for measuring protein expression levels thereof, and a method for detecting a marker form a sample obtained from a test subject in order to provide information necessary for diagnosing colorectal cancer. The colorectal cancer diagnostic marker comprising KRS and AIMP1, according to the present invention, has raised expression levels of same in the serum of a colorectal cancer patient in comparison to a normal control group. Therefore, whether colorectal cancer is present can be accurately and rapidly determined by measuring the expression levels of one or more markers selected from the group consisting of KRS and AIMP1.

Abstract: The present invention relates to an EPRS (glutamyl-prolyl-tRNA synthetase) protein or a fragment thereof. The EPRS protein of the present invention or fragment thereof may bind to PCBP2 protein to activate the MAVS signaling pathway, and thus it has anti-RNA viral effects, thereby being effective for preventing or treating a RNA viral infectious disease.

Abstract: Disclosed are a window apparatus for obtaining a microscopic image of in vivo breast tissue and a method for using the window apparatus to obtain cell-level and molecular-level microscopic images of in vivo breast tissue while maintaining the biological environment of the in vivo breast tissue. In one embodiment, a window apparatus comprises a first chamber having a ring structure with an open window on the center, and a cover glass disposed on the upper part and breast tissue placed on the lower part; a second chamber having an opening window on the center coupled to the first chamber to support the breast tissue; and a chamber holder for fixing the first and second chambers having a tilting mount placing unit with the tilting mount placed to have the cover glass and an object lens of a confocal microscope system stay parallel to each other.

Abstract: A method for diagnosing follicular thyroid carcinoma is described. The method measures protein expression levels of an aminoacyl-tRNA synthetase (ARS) or an aminoacyl-tRNA synthetase complex-interacting multifunctional protein (AIMP) in a sample, such as a thyroid tissue sample, from a subject suspected of having follicular thyroid carcinoma. The protein expression levels of ARS or AIMP are compared to the measured protein expression levels in a control.

Abstract: A polypeptide having chemokine activity mediated by binding to C-C chemokine receptor type 3 (CCR3) comprising SEQ ID NO: 1 and uses thereof are described.

Abstract: The present invention relates to an EPRS (glutamyl-prolyl-tRNA synthetase) protein or a fragment thereof. The EPRS protein of the present invention or fragment thereof may bind to PCBP2 protein to activate the MAVS signaling pathway, and thus it has anti-RNA viral effects, thereby being effective for preventing or treating a RNA viral infectious disease.

Abstract: Disclosed are a microaspiration-based lung window apparatus for obtaining a microscopic image of in vivo lung tissue and a method for using the window apparatus to obtain cell-level and molecular level microscopic images of in vivo lung tissue while maintaining physiological respiration and circulation of an animal without interference. In one embodiment, a lung window apparatus comprises an open window having the upper and lower parts open, a cover glass placed over the upper part and lung tissue coming in contact with the lower part; an aspiration tube extending from one side of the open window to an aspiration apparatus enabling the inside of the open window to be in a vacuum state; and a tilting mount placing unit extending from one side of the open window having a tilting mount to enable the cover glass and an object lens of a confocal microscope system to stay parallel to each other.

Abstract: The present invention relates to nanoparticles comprising aminoacyl tRNA synthetase and an anticancer composition comprising the same and, specifically, to nanoparticles which comprise glycyl-tRNA synthetase (GRS), leucyl-tRNA synthetase (LRS), and isoleucyl-tRNA synthetase (IRS), and have anticancer or immunostimulating activity; a pharmaceutical composition for preventing or treating cancer, comprising the nanoparticles as an active ingredient; a composition for immunostimulation; and a method for preparing the nanoparticles.

Abstract: Provided is a bio chip structure for a comparative experiment. The bio chip structure for a comparative experiment according to the present invention may include: a first pillar substrate including at least one first pillar where a first sample is disposed; a second pillar substrate including at least one second pillar where a second sample is disposed; and a well substrate including wells to which at least one pair of the first pillars of the first pillar substrate and the second pillar of the second pillar substrate is inserted. Accordingly, a comparative experiment to culture a different kind of samples may be conducted in an identical environment, a different kind of samples, which are the subjects of a comparative experiment, may be rapidly and accurately disposed on a plurality of pillars, and an experimental group or a control group may be easily replaced.

Abstract: The present invention relates to an antibody specifically binding to PICP or a fragment thereof; an enzyme-linked immunosorbent assay (ELISA) kit and a composition for diagnosing metabolic bone diseases, both of which contain the same; a method for detecting PICP by using the same; a polynucleotide encoding the antibody or a fragment, and a recombinant expression vector comprising the same; cells transformed by the recombinant expression vector; and a method for preparing an antibody specifically binding to PICP or a fragment thereof by using the recombinant expression vector, and a method for preparing a recombinant PICP protein.

Abstract: The present invention relates to a novel function of lysyl tRNA synthetase, that is, lysyl tRNA synthetase interacts with 67LR through translocation of KRS into plasma membrane, and so enhances tumor (or cancer) cell migration, thereby having an effect on cancer metastasis. More specifically, it relates to method for controlling cancer metastasis or cancer cell migration by modulating an cellular level of lysyl tRNA synthetase, an use of an expression vector comprising a construct inhibiting KRS expression for preventing or treating cancer, an use of an agent inhibiting KRS activity for preventing or treating cancer, a method for screening an agent which modulates cancer metastasis or cancer cell migration, a method for screening an agent inhibiting an interaction between KRS and 67LR. Accordingly, cancer metastasis and cancer cell migration may be controlled using the inventive KRS, further the cellular metabolism related to laminin receptor (67LR) of plasma membrane may be controlled.

Abstract: This application relates to a novel benzo-heterocycle derivative and more particularly, it relates a composition for preventing and treating cancer or for inhibiting metastasis comprising benzo-heterocycle derivative or pharmaceutically acceptable salts thereof as an active ingredient. The present inventors confirmed that KRS has an effect on cancer metastasis by facilitating cancer (or tumor) cell migration through interaction with 67LR, and also found that a substance inhibiting the interaction between KRS and 67LR can prevent and treat cancer by inhibiting cancer cell metastasis. Accordingly, the composition of the present invention can inhibit cancer metastasis, and thus provide a novel means for prevention and treatment of cancer.

Abstract: Disclosed are a microaspiration-based lung window apparatus for obtaining a microscopic image of in vivo lung tissue and a method for using the window apparatus to obtain cell-level and molecular level microscopic images of in vivo lung tissue while maintaining physiological respiration and circulation of an animal without interference. In one embodiment, a lung window apparatus comprises an open window having the upper and lower parts open, a cover glass placed over the upper part and lung tissue coming in contact with the lower part; an aspiration tube extending from one side of the open window to an aspiration apparatus enabling the inside of the open window to be in a vacuum state; and a tilting mount placing unit extending from one side of the open window having a tilting mount to enable the cover glass and an object lens of a confocal microscope system to stay parallel to each other.

Abstract: The present invention relates to an anti-lysyl-tRNA synthetase (KRS) antibody selectively binding to KRS, and a use thereof and, more specifically, to an antibody binding to human KRS or a fragment thereof, a method for producing the same, and a composition containing the same for diagnosing cancer, autoimmune diseases or inflammatory diseases. The antibody or fragment thereof of the present invention specifically binds to human KRS, and enables KRS detection and inhibition due to the absence of cross-linkage reactivity with the other proteins including the same ARS family, and thus the antibody or fragment thereof can be used to detect KRS and diagnose KRS-related diseases, i.e., cancer, autoimmune diseases or inflammatory diseases.

Abstract: Described herein are an antibody specifically binding to AIMP2-DX2 protein, and a diagnostic kit for detecting cancer which comprises the antibody specific to the AIMP2-DX2.

Abstract: Exemplary embodiments relate to a novel anticancer composition including a compound represented by chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient:

Abstract: The present invention relates to a novel function of lysyl tRNA synthetase (KRS) which enhances tumor cell migration and affects cancer metastasis via KRS's interaction with laminin receptor (67LR) by its translocation to membrane. More particularly, the present invention relates to a method for modulating cancer metastasis or migration, which comprises regulating intracellular levels of KRS; a composition for preventing or treating cancer; use of expression vector for inhibiting the expression of KRS; a method for preventing or treating cancer; use of an agent for inhibiting an activity of KRS; a method for screening an agent which modulates cancer metastasis or migration; and a method for screening an agent which inhibits the interaction of KRS with 67LR, by said novel function. Thus, KRS can modulate cancer metastasis or migration and furthermore, can modulate intracellular metabolism related to 67LR.

Abstract: Provided is a method of screening for agents for preventing or treating mTORC 1 mediated diseases by screening test agents to determine test agents that inhibit the binding ability of LRS to RagD, or RagD GTPases, and a method of reducing cell size as compared to the control group, including inhibiting the expression of intracellular LRS in the cells.